Skip to main content
. 2014 Jul 16;20:1227–1231. doi: 10.12659/MSM.890270

Figure 1.

Figure 1

The percentage of aCL and B2GP-I in IgM and IgG classes at the beginning and after 3 and 6 months of rheumatoid arthritis treatment with infliximab.